The prophylaxis ofpulmonary surfactant on hyaline membrane disease in preterm infants with differentgestatiooal ages

：Objective To evaluatethe clinical effects and safety of pulmonary surfactant (PS) on-hya line membrane disease(HMD) in preterm infants of different gestational ages, and to discuss the bestopportu-nity for prophylaxis on HMD with PS. Methods Nine hundred and eleven preterminfants with gestational a-ges (GA) ＜35 weeks were analyzedretrospectively,among which 146 babies given PS prophylactically were classified as GroupA,and the other 765 babies without PS as Group B. HMD morbidity and mortality within 7days,as well as the period of mechanical ventilation,oxygen therapy and hospitalizationand major complica-tions were analyzed statistically in both groups. Results Compared toGroup B,HMD morbidity within 7 days was significantly lower by 28. 1% (P＜ 0.05) in Group A. HMD morbidities within 7 days in babies with GA＜ 30 weeks,GA =30 weeks and 31 weeks of Group A werereduced by 43.2% ,58.4% and 50.9% respectively. A significant difference in the 7-daysmortality was observed between Group A (6.2%) and Group B (18.2% ). The mortality ofbabies with GA <30 weeks,GA =30 weeks,GA =31 weeks in Group A reduced by 23.0% ,26.0%and 17.6% respectively with prophylactic administration of PS. There were significantdiffer-ences in the time of ventilation and oxygen therapy (P ＜ 0.05), but no difference was showed in the time of hospitalization between twogroups( P ＞0.05). Compared to Group B,Group A had a lower incidence of lunghemorrhage, ventilator-associated pneumonia and air leak (P＜0.05). ConclusionProphylactic administration of PS results in lower HMD morbidity and mortality,shorteningthe time of ventilation and oxygen therapy, as well as reducing complication incidencesuch as lung hemorrhage,ventilator-associated pneumonia,air leak,par-ticularly in thepreterm infants with GA≤31 weeks. Key words: Infant,newborn,preterm; Hyaline membrane disease; Pulmonarysurfactant; Gestational age